Tyra Biosciences/$TYRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Ticker
$TYRA
Sector
Primary listing
Employees
60
Headquarters
Website
Tyra Biosciences Metrics
BasicAdvanced
$667M
-
-$1.79
1.08
-
Price and volume
Market cap
$667M
Beta
1.08
52-week high
$27.66
52-week low
$6.42
Average daily volume
219K
Financial strength
Current ratio
21.943
Quick ratio
21.639
Long term debt to equity
1.847
Total debt to equity
1.993
Profitability
EBITDA (TTM)
-121.072
Management effectiveness
Return on assets (TTM)
-21.29%
Return on equity (TTM)
-31.21%
Valuation
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-8.548
Free cash flow yield (TTM)
-11.70%
Free cash flow per share (TTM)
-1.465
Growth
Earnings per share change (TTM)
8.69%
3-year earnings per share growth (CAGR)
8.84%
What the Analysts think about Tyra Biosciences
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Bulls say / Bears say
Tyra held $296.3 million in cash and marketable securities as of June 30, 2025, providing funding through at least 2027 for its clinical programs.
Tyra achieved major pipeline milestones in the first half of 2025, including dosing the first HCC patient in SURF431, the first NMIBC patient in SURF302, and opening enrollment for BEACH301 in pediatric achondroplasia.
Interim proof-of-concept data from the SURF301 study showed strong anti-tumor activity and good tolerability in heavily pre-treated metastatic urothelial cancer patients, supporting confidence in TYRA-300's potential.
Cash declined from $341.4 million at year-end 2024 to $296.3 million by June 30, 2025, a drop of about 13% in six months, raising the likelihood of future dilutive financing.
Tyra reported a net loss of $28.1 million for Q2 2025, highlighting high operating expenses with no incoming revenues, increasing strain on capital resources.
Key Phase 2 results for SURF302 and BEACH301 are not expected until late 2025 or the first half of 2026, meaning there won't be significant clinical milestones to boost the stock in the near term.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Tyra Biosciences Financial Performance
Revenues and expenses
Tyra Biosciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tyra Biosciences stock?
Tyra Biosciences (TYRA) has a market cap of $667M as of September 15, 2025.
What is the P/E ratio for Tyra Biosciences stock?
The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of September 15, 2025.
Does Tyra Biosciences stock pay dividends?
No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Tyra Biosciences dividend payment date?
Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tyra Biosciences?
Tyra Biosciences (TYRA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.